












INNOVATIVE PIPELINE HAS DELIVERED 15 NEW MOLECULAR ENTITY CLINICAL STAGE-UPS SINCE APRIL 2018

	PHASE 1	PHASE 2	PHASE 3/FILED	APPROVED*						
 ONCOLOGY	<p>TAK-252 <i>Shattuck</i> Agonist Redirected Checkpoint Solid tumors</p> <p>TAK-164 <i>ImmunoGen</i> GCC IGM ADC GI malignancies</p>	<p>TAK-573 <i>Teva</i> Anti-CD38/attenukine R/R MM</p> <p>TAK-981 SUMO1 inhibitor Multiple cancers</p>	<p>TAK-079 Anti-CD38 mAb R/R MM, SLE</p>	<p>TAK-228 <i>(Epanisertib)</i> mTORC 1/2 inhibitor Endometrial cancer</p> <p>TAK-788 EGFR/HER2 inhibitor NSCLC</p>	<p>TAK-659 SYK/FLT-3 inhibitor Hematologic malignancies, NHL</p> <p>TAK-931 CDC7 inhibitor ESCC, sqNSCLC</p>	<p>TAK-385 <i>(ralugolis)</i> <i>Myovant</i> GnRH antagonist Prostate Cancer (IP)</p> <p>TAK-924 <i>(pevonedistat)</i> VWE inhibitor HR-MDS/CMML</p>	<p>NINLARO Proteasome inhibitor</p> <p>ALUNBRIG ALK inhibitor</p>	<p>ADCETRIS <i>Seattle Genetics</i> CD30 ADC</p> <p>Cabozantinib <i>Eli Lilly</i> VEGFR/RTK inhibitor</p>	<p>ICLUSIG BCR-ABL inhibitor</p> <p>Niraparib <i>GlaxoSmithKline</i> PARP 1/2 inhibitor</p>	
 GASTRO-ENTEROLOGY	<p>TAK-951 Peptide agonist Nausea & vomiting</p> <p>TAK-681 <i>(SHP-681)</i> GLP2r long-acting Short Bowel Syndrome</p>	<p>Kuma062 <i>Pvp Biologics</i> Glutenase Celiac Disease</p> <p>TAK-671 <i>Sansung Biopis</i> Protease inhibitor Acute Pancreatitis</p>	<p>TAK-018 <i>Enterome</i> FimH antagonist Crohn's Disease</p>	<p>TAK-906 D2/D3R antagonist Gastroparesis</p> <p>TAK-954 <i>Theravance</i> 5-HT4R agonist POGD</p>	<p>TIMP-Gliadin <i>Cour</i> Imm Tol Induction Celiac Disease</p>	<p>TAK-721 <i>(SHP621)</i> <i>UCSD/ Fortis</i> Oral anti-inflammatory EOE</p>	<p>ENTYVIO α4β7 mAb</p> <p>GATTEX GLP-2R agonist</p>	<p>Vonoprazan PCAB</p>	<p>ALOFISEL mesenchymal stem cells</p>	
 RARE DISEASES	<p>TAK-611 <i>(SHP611)</i> ERT MLD</p>	<p>TAK-531 <i>(SHP531)</i> <i>ArmaGen</i> I2S replacement Hunter CNS</p>	<p>TAK-754 <i>(SHP654)</i> <i>Asklepias Biopharm.</i> Gene therapy HemaA</p>	<p>TAK-607 <i>(SHP607)</i> IGF-1/IGFBP3 Chronic Lung Disease</p>	<p>TAK-609 <i>(SHP609)</i> I2S replacement Hunter CNS (IT)</p>	<p>TAK-755 <i>(SHP655)</i> <i>KIM Biologics</i> ERT/ ADAMTS-13 CTP</p>	<p>TAK-620 <i>(SHP620)</i> <i>GlaxoSmithKline</i> UL97 kinase inh CMV/ infect. in transplant</p>	<p>OBIZUR <i>Ipsen</i> FVIII replacement</p> <p>ADYNOVATE FVIII replacement</p>	<p>VONVENDI vWF replacement</p> <p>TAKHZYRO Anti-kallikrein mAb</p>	<p>NATPARA PTH replacement</p>
 NEUROSCIENCE	<p>TAK-653 AMPA/R potentiator TRD</p> <p>MEDI-1341 <i>AstraZeneca</i> Alpha-syn mAb Parkinson's Disease</p> <p>WVE-120101 <i>Wave Life Sciences</i> mHTT SNP1 ASO Huntington's Disease</p>	<p>TAK-418 LSD1 inhibitor Kabuki Syndrome</p> <p>TAK-925 Orexin 2R agonist Narcolepsy</p> <p>WVE-120102 <i>Wave Life Sciences</i> mHTT SNP2 ASO Huntington's Disease</p>	<p>TAK-041 GPR139 agonist CIAS NS</p>	<p>TAK-935 <i>Ovid Therapeutics</i> CH24H inhibitor Rare Pediatric Epilepsies</p>	<p>TAK-831 DAAO inhibitor CIAS NS</p>		<p>TRINTELLIX <i>Lundbeck</i> Multimodal anti-depressant</p>	<p>BUCCOLAM GABA Allosteric Modulator</p>		
 PLASMA-DERIVED THERAPIES							<p>HYQVIA <i>Halozyme</i> IgG 10% + Recombinant Human Hyaluronidase</p>	<p>CINRYZE C1 inhibitor</p>		
 VACCINES	<p>TAK-021 EV71 Vaccine</p>	<p>TAK-426 <i>BARDA</i> Zika Vaccine</p>	<p>TAK-214 Norovirus Vaccine</p>	<p>TAK-003 Dengue Vaccine</p>						

*With ongoing significant clinical development activities; Pipeline as of May 14, 2019
Pipeline not all inclusive; programs also ongoing in other Therapeutic Areas. For glossary of disease abbreviations please refer to appendix.

- ▶ Stage-ups/additions after Q3 FY18
- ▶ Stage-ups/additions since April 1, 2018
- Orphan Drug Designation (in any region / indication for a given asset)
- Registration enabling Ph-2 study
- Assets shown in Phases 1-3 explicitly refer to new molecular entities

MAXIMIZING THE VALUE OF OUR APPROVED PROGRAMS

	PHASE 1	PHASE 2	PHASE 3	FILED	
 ONCOLOGY	<p>ALUNBRIG* ALK inhibitor 1L ALK+NSCLC (CN)</p>	<p>ALUNBRIG* ALK inhibitor 2L ALK+NSCLC (JP, CN)</p> <p>ICLUSIG* BCR-ABL inhibitor TKI res. chronic phase CML (US)</p> <p>ALUNBRIG* ALK inhibitor 2L ALK+NSCLC 2nd gen TKI (GL)</p>	<p>Cabozantinib <i>Exelixis</i> VEGFR/RTK inhibitor 2L HCC (JP)</p> <p>NINLARO* Proteasome inhibitor R/R MM triplet Tx (GL)</p> <p>Niraparib <i>GlaxoSmithKline</i> PARP 1/2 inhibitor Ovarian cancer – maint. (JP)</p> <p>Niraparib <i>GlaxoSmithKline</i> PARP 1/2 inhibitor Ovarian cancer – salvage (JP)</p>	<p>ADCRETIS* <i>Seattle Genetics</i> CD30 ADC 1L PTCL (EU)</p> <p>ALUNBRIG* ALK inhibitor 1L ALK+NSCLC (EU, US)</p> <p>ICLUSIG* BCR-ABL inhibitor FL Ph+ ALL (US)</p> <p>NINLARO* Proteasome inhibitor R/R MM doublet Tx (US, EU, JP)</p> <p>NINLARO* Proteasome inhibitor ND MM (GL)</p> <p>Cabozantinib <i>Exelixis</i> VEGFR/RTK inhibitor 1L RCC (JP)</p> <p>NINLARO* Proteasome inhibitor Maint. ND MM post-SCT (GL)</p> <p>NINLARO* Proteasome inhibitor ND MM (GL)</p> <p>NINLARO* Proteasome inhibitor ND MM (GL)</p> <p>NINLARO* Proteasome inhibitor ND MM (GL)</p> <p>NINLARO* Proteasome inhibitor ND MM (GL)</p>	<p>ADCRETIS* <i>Seattle Genetics</i> CD30 ADC R/R sALCL (CN)</p> <p>ADCRETIS* <i>Seattle Genetics</i> CD30 ADC 1L PTCL (JP)</p> <p>ADCRETIS* <i>Seattle Genetics</i> CD30 ADC 2L ALK+NSCLC HZH with alectinib (GL)</p> <p>ADCRETIS* <i>Seattle Genetics</i> CD30 ADC R/R HL (CN)</p> <p>Cabozantinib <i>Exelixis</i> VEGFR/RTK inhibitor 2L RCC (JP)</p> <p>NINLARO* Proteasome inhibitor Maint. ND MM post-SCT (JP)</p>
 GASTRO- ENTEROLOGY		<p>Vonoprazan PCAB GERD PPI partial resp (EU)</p>	<p>ALOFISEL* mesenchymal stem cells Perianal Fistulas in CD (US, JP)</p> <p>ENTYVIO* α4β7 mAb SubQ UC (US, JP)</p> <p>ENTYVIO* α4β7 mAb SubQ CD (US, JP)</p> <p>ENTYVIO* α4β7 mAb Ulcerative Colitis (CN)</p> <p>GATTEX GLP-2R agonist Pediatric-SBS (JP)</p> <p>GATTEX GLP-2R agonist Adult-SBS (JP)</p> <p>ENTYVIO* α4β7 mAb Crohn's Disease (CN)</p> <p>ENTYVIO* α4β7 mAb adalimumab HZH (GL)</p>	<p>ENTYVIO* α4β7 mAb Crohn's Disease (JP)</p> <p>ENTYVIO* α4β7 mAb SubQ UC (EU)</p> <p>GATTEX GLP-2R agonist Pediatric-SBS (US)</p> <p>ENTYVIO* α4β7 mAb SubQ CD (EU)</p> <p>Vonoprazan PCAB Acid-related diseases (CN)</p>	
 RARE DISEASES	<p>NATPARA PTH replacement Hypothyroidism (JP)</p>		<p>OBIZUR <i>Ipsen</i> FVIII replacement CHAWI (US, EU)</p> <p>ADYNOVATE Pediatric Hem A (EU)</p> <p>VONVENDI vWF replacement vWD Prophylaxis</p> <p>VONVENDI vWF replacement vWD Pediatric</p>	<p>TAKHZYRO Anti-kallikrein mAb HAE prophylaxis (CN)</p>	
 NEUROSCIENCE			<p>BUCCOLAM GABA Allosteric Modulator Status Epilepticus (JP)</p>	<p>TRINTELLIX™ <i>Lundbeck</i> Multimodal anti-depressant MDD (JP)</p>	
 PLASMA-DERIVED THERAPIES			<p>CINRYZE C1-inh HAE prophylaxis (JP)</p> <p>HYQVIA <i>Halozyme</i> IgG 10% + Recombinant Human Hyaluronidase CIDP</p> <p>HYQVIA <i>Halozyme</i> IgG 10% + Recombinant Human Hyaluronidase Pediatric PID (US)</p>		

- ▶ Stage-ups/additions after Q3 FY18
- ▶ Stage-ups/additions since April 1, 2018
- Orphan Drug Designation
(in any region / indication for a given asset)
- Registration enabling Ph-2 study